Research Areas

Long framed as a gynecological condition, PMOS is now understood as a multisystem disorder with metabolic, psychological, and cardiovascular consequences.

As gene editing advances, legacy off-target screening approaches are struggling to keep pace with increasing biological and regulatory complexity.

The FDA announced interest in advancing drug repurposing programs across a wide variety of conditions, though challenges remain.

As discovery programs grow in complexity and throughput demands accelerate, automation has moved from a convenience to a core requirement for generating reliable, reproducible data at scale.

Mass photometry helps researchers investigate the large and dynamic molecular assemblies that drive HIV integration and influence antiviral drug development.

A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses.

As multiplexing platforms become more scalable and flexible, biomarkers are playing an increasingly central role in both preclinical and clinical decision-making.

Study demonstrates that computationally-designed miniproteins can modulate GPCR activity in native cellular environments, expanding access to a major drug target family.

An integrated workflow brings charge and size analysis together for faster, more informative bispecific antibody characterization. 

Pharma deals, FDA  review hurdles, and more led the news this week.